Efficacy and Safety of NVX-CoV2705
COVID-19
A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Post-Marketing Study to Evaluate the Efficacy and Safety of an Omicron JN.1 Subvariant SARS-CoV-2 rS Vaccine Adjuvanted With Matrix-M® in Adults 50 to < 65 Years of Age Without High Risk Conditions for Severe COVID-19
1 other identifier
interventional
6,500
1 country
99
Brief Summary
This is a Phase 4, post-market US study, evaluating the efficacy and safety of a single dose of the NVX-CoV2705 Omicron JN.1 COVID-19 vaccine. Approximately 6,500 healthy adults aged 50 to under 65 will be randomized to receive either the vaccine or a placebo, with follow-up for 180 days.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_4 covid19
Started Nov 2025
Typical duration for phase_4 covid19
99 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 17, 2025
CompletedFirst Posted
Study publicly available on registry
July 25, 2025
CompletedStudy Start
First participant enrolled
November 20, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 18, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 18, 2026
May 8, 2026
May 1, 2026
12 months
July 17, 2025
May 6, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
First episode of PCR-positive symptomatic COVID 19
First episode of PCR-positive symptomatic COVID 19 from Day 0 (post vaccination) through Day 180/EoS
Day 0 to Day 180
Secondary Outcomes (2)
First episode of PCR-positive symptomatic COVID 19
Day 42 to Day 180
Participants with Medically attended adverse events (MAAEs), Serious adverse event (SAEs) and Adverse event of special interest (AESIs)
Day 180
Study Arms (2)
NVX-CoV2705
EXPERIMENTALa single intramuscular (IM) injection of NVX-CoV2705 on Day 0
Placebo
PLACEBO COMPARATORa single intramuscular (IM) injection of placebo (normal saline) on Day 0
Interventions
NVX-CoV2705 vaccine in a 0.5 mL injection volume at an antigenic dose of 5 µg with 50 µg Matrix-M adjuvant
Eligibility Criteria
You may qualify if:
- To be included in this study, each individual must satisfy all of the following criteria:
- Adults 50 to \< 65 years of age at time of study vaccination (Day 0) who are not considered to be at high risk of severe COVID-19.
- Participants unvaccinated to SARS-CoV-2 or participants previously vaccinated with a COVID-19 vaccine ≥ 90 days prior to study vaccination.
- Participant or legally acceptable representative is willing and able to give informed consent prior to study enrollment and to comply with study procedures.
- Female participants of childbearing potential (defined as any participant who has experienced menarche and who is NOT surgically sterile \[ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy\] or postmenopausal \[defined as amenorrhea ≥ 12 consecutive months\]) must agree to be heterosexually inactive from at least 28 days prior to enrollment and through 90 days after vaccination OR agree to consistently use a medically acceptable method of contraception listed below from ≥ 28 days prior to enrollment and through 90 days after vaccination.
- Condoms (male or female) with spermicide (if acceptable in country)
- Diaphragm with spermicide
- Cervical cap with spermicide
- Intrauterine device
- Oral or patch contraceptives
- Norplant®, Depo-Provera®, or other in country regulatory approved contraceptive method that is designed to protect against pregnancy
- Abstinence, as a form of contraception, is acceptable if in line with the participant's lifestyle NOTE: Periodic abstinence (eg, calendar, ovulation, sympto-thermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
- Agrees not to participate in any research involving receipt of investigational products (drug/biologic/device), including other SARS-CoV-2 prevention or treatment trials, for the duration of the study.
You may not qualify if:
- If an individual meets any of the following criteria, he or she is ineligible for this study:
- Is considered to be at high risk of severe COVID-19 due to underlying medical conditions or risk factors that demonstrated a conclusive increase in risk for at least one severe COVID-19 outcome, as described by the Centers for Disease Control and Prevention (CDC) .
- Unstable acute illness at the time of vaccination.
- Participation at the time of study enrollment or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure.
- Current participation in any other COVID-19 prevention clinical trial.
- Known history of COVID-19 infection within 90 days of study vaccination.
- Any known history of allergies to products contained in the investigational product in the participant's lifetime.
- Any known history of anaphylaxis to any prior vaccine in the participant's lifetime.
- Known history of myocarditis or pericarditis in the participant's lifetime.
- Chronic administration (defined as \> 14 continuous days) of immunosuppressant, systemic glucocorticoids, or other immune-modifying drugs within 90 days prior to study vaccination (Day 0).
- NOTE: An immunosuppressant dose of glucocorticoid is defined as a systemic dose ≥ 10 mg of prednisone per day or equivalent. The use of topical, inhaled, or intranasal glucocorticoids is permitted. Topical tacrolimus and ocular cyclosporin are permitted.
- Received immunoglobulin or blood-derived products within 90 days prior to study vaccination (Day 0).
- Participants who are pregnant, or who plan to become pregnant within 90 days following study vaccination.
- Any other condition that, in the opinion of the investigator, would pose a health risk to the participant if enrolled or could interfere with evaluation of the study vaccine or interpretation of study results (including neurologic or psychiatric conditions likely to impair the quality of safety reporting).
- Study team member or immediate family member of any study team member (inclusive of Sponsor, clinical research organization \[CRO\], and study site personnel involved in the conduct or planning of the study).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (99)
North Alabama Research Center
Athens, Alabama, 35611, United States
TrialMed - Birmingham
Birmingham, Alabama, 35211, United States
Hawthorne Health - Gadsden
Gadsden, Alabama, 35901, United States
TrialdMed - Huntsville
Huntsville, Alabama, 35802, United States
AMR Mobile
Mobile, Alabama, 36608, United States
Headlands Research Scottsdale
Scottsdale, Arizona, 85260, United States
Orange Grove Family Practice
Tucson, Arizona, 85741, United States
310 Clinical Research
Inglewood, California, 90301, United States
Velocity Clinical Research - San Diego
La Mesa, California, 91942, United States
Profound Research LLC at Seaside Medical Group
Oceanside, California, 92058, United States
California Research Foundation
San Diego, California, 92123, United States
Bayview Research Group, LLC
Valley Village, California, 91607, United States
Diablo Clinical Research, Inc.
Walnut Creek, California, 94598, United States
Alliance Clinical - West Hills
West Hills, California, 91303, United States
Lynn Institute of Denver
Aurora, Colorado, 80012, United States
Paradigm Clinical Research Centers, LLC
Wheat Ridge, Colorado, 80033, United States
Clinical Research Consulting, LLC
Milford, Connecticut, 06460, United States
SIMED Health, LLC / SIMED Research
Gainesville, Florida, 32607, United States
Indago Research and Health Center, Inc.
Hialeah, Florida, 33012, United States
Health Awareness, LLC
Jupiter, Florida, 33458, United States
TrialMed - Melbourne
Melbourne, Florida, 32934, United States
Acevedo Clinical Research Associates
Miami, Florida, 33142, United States
Research Institute Of South Florida, Inc.
Miami, Florida, 33173, United States
MOORE Clinical Research
Tampa, Florida, 33609, United States
TrialMed - The Villages
The Villages, Florida, 32162, United States
Palm Beach Research Center
West Palm Beach, Florida, 33409, United States
CenExel Atlanta GA
Atlanta, Georgia, 30331, United States
Centricity Research
Columbus, Georgia, 31904, United States
Clinical Research Atlanta
Stockbridge, Georgia, 30281, United States
Velocity Clinical Research, Boise
Meridian, Idaho, 83642, United States
Accellacare of Duly
Lombard, Illinois, 60148, United States
Accellacare Duly Health and Care
Oak Lawn, Illinois, 60453, United States
TrialMed
Evansville, Indiana, 47714, United States
Velocity Clinical Research, Valparaiso
Valparaiso, Indiana, 46383, United States
Velocity Clinical Research, Sioux City
Sioux City, Iowa, 51106, United States
Integrated Clinical Trial Services
West Des Moines, Iowa, 50265, United States
DelRicht Research @ Concierge and Direct Primary Care
Overland Park, Kansas, 66209, United States
Alliance for Multispecialty Research, LLC
Wichita, Kansas, 67207, United States
Alliance for Multispecialty Research, L.L.C.
Lexington, Kentucky, 40509, United States
DelRicht Research @ Touro Medical Center
New Orleans, Louisiana, 70115, United States
DelRicht Research @ Matthew Mintz Clinic
Rockville, Maryland, 20852, United States
Profound Research LLC at Millennium Affiliated Physicians
Farmington Hills, Michigan, 48334, United States
Great Lakes Research Institute, LLC
Southfield, Michigan, 48075, United States
Clinical Research Institute, Inc
Minneapolis, Minnesota, 55402, United States
DelRicht Research at Gulfport Memorial
Gulfport, Mississippi, 39503, United States
AMR Kansas City
Kansas City, Missouri, 64114, United States
Sundance Clinical Research
St Louis, Missouri, 63141, United States
Boeson Research
Missoula, Montana, 59804, United States
Velocity Clinical Research, Lincoln
Lincoln, Nebraska, 68510, United States
Velocity Clinical Research
Norfolk, Nebraska, 68701, United States
Velocity Clinical Research, Omaha
Omaha, Nebraska, 68134, United States
Excel Clinical Research
Las Vegas, Nevada, 89109, United States
TrialMed - Las Vegas
Las Vegas, Nevada, 89113, United States
AMR Clinical - Las Vegas
Las Vegas, Nevada, 89119, United States
Hawthorne Health - Lindenwold
Lindenwold, New Jersey, 08021, United States
IMA Clinical Research - Albuquerque
Albuquerque, New Mexico, 87109, United States
Velocity Clinical Research - Binghampton
Binghamton, New York, 13905, United States
Rochester Clinical Research
Buffalo, New York, 14217, United States
Rochester Clinical Research, LLC
Rochester, New York, 14609, United States
Hawthorne Health - Staten
Staten Island, New York, 10309, United States
Hawthorne Health - Concord
Concord, North Carolina, 28025, United States
Monroe Pharmaceutical Research
Monroe, North Carolina, 28112, United States
Accellacare of Rocky Mount
Rocky Mount, North Carolina, 27804, United States
Accellacare Research of Salisbury
Salisbury, North Carolina, 28144, United States
Accellacare Research of Winston Salem
Winston-Salem, North Carolina, 27103, United States
DSI Research - Northridge
Dayton, Ohio, 45414, United States
Lynn Institute of Norman
Norman, Oklahoma, 73072, United States
Lynn Health Institute - OKC
Oklahoma City, Oklahoma, 73112, United States
DelRicht Research @ Grassroots Healthcare
Tulsa, Oklahoma, 74133, United States
Velocity Clinical Research, Medford
Medford, Oregon, 97504, United States
Capital Area Research, LLC
Camp Hill, Pennsylvania, 17011, United States
Hawthorne Health - Horsham
Horsham, Pennsylvania, 19044, United States
Suburban Research Associates - West Chester Office
West Chester, Pennsylvania, 19380, United States
K2 Medical Research - East Providence
East Providence, Rhode Island, 02914, United States
DelRicht Research @ Newton Family Medicine
Charleston, South Carolina, 29407, United States
Piedmont Research Partners
Fort Mill, South Carolina, 29707, United States
Trial Management Associates (TMA ) Headlands LLC
Myrtle Beach, South Carolina, 29572, United States
Accellacare of Bristol
Bristol, Tennessee, 37620, United States
WR Clinsearch, LLC
Chattanooga, Tennessee, 37421, United States
Summit-Halls Family Practice
Knoxville, Tennessee, 37938, United States
Hawthorne Health - Lebanon
Lebanon, Tennessee, 37087, United States
International Clinical Research - Tennessee
Murfreesboro, Tennessee, 37130, United States
Avacare
Austin, Texas, 78705, United States
TrialMed - Austin
Austin, Texas, 78744, United States
Howland Allergy & Asthma PLLC dba Orion Clinical Research
Austin, Texas, 78759, United States
Zenos Clinical Research
Dallas, Texas, 75230, United States
Avacare
Fort Worth, Texas, 76135, United States
SMS Clinical Research LLC
Mesquite, Texas, 75149, United States
ACRC Trials
Plano, Texas, 75093, United States
Research Your Health
Plano, Texas, 75093, United States
Flourish San Antonio - Clinical
San Antonio, Texas, 78229, United States
TrialMed - San Antonio
San Antonio, Texas, 78229, United States
Sugar Lakes Family Practice, P.A.
Sugar Land, Texas, 77479, United States
Boeson Research - Utah
Provo, Utah, 84604, United States
University of Utah
Salt Lake City, Utah, 84108, United States
J. Lewis Research, Inc. / Foothill Family Clinic
Salt Lake City, Utah, 84109, United States
Charlottesville Medical Research Center, LLC
Charlottesville, Virginia, 22911, United States
Health Research of Hampton Roads, Inc
Newport News, Virginia, 23606, United States
Velocity Clinical Research, Seattle
Seattle, Washington, 98105, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Clinical Development
Novavax, Inc.
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, CARE PROVIDER
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 17, 2025
First Posted
July 25, 2025
Study Start
November 20, 2025
Primary Completion (Estimated)
November 18, 2026
Study Completion (Estimated)
November 18, 2026
Last Updated
May 8, 2026
Record last verified: 2026-05